Statin prescribing is one of the highest-volume, lowest-complexity repeat categories in UK primary care, which makes it a natural fit for telehealth once the monitoring loop is built properly. Get the lipid panel gate, the referral boundaries and the intolerance pathway right, and it becomes a steady, low-churn addition to an existing brand rather than a new clinical risk centre.
Why lipid management suits the UK telehealth model
Millions of adults in the UK are on a statin for primary or secondary cardiovascular prevention, and most of those relationships are repeat prescriptions with an annual review rather than complex, ongoing clinical decision-making. That profile, high repeat volume, low per-visit complexity, is exactly what a remote pathway does well.
Brands already running a hypertension or type 2 diabetes vertical have a head start: the risk-stratification intake, the monitoring cadence and the review-reminder infrastructure largely carry over, so cholesterol becomes an extension of an existing cardio-metabolic offer rather than a build from zero.
What's in scope, and what belongs with a specialist lipid clinic
In scope for a well-run telehealth pathway: primary prevention in adults with an elevated cardiovascular risk score, and straightforward secondary prevention once a patient is stable and has been discharged from acute cardiology care. Switching statin, dose or brand for tolerability reasons also sits comfortably within a remote model, provided the prescriber has a clear picture of what's already been tried.
The line moves quickly once the case gets more complex, and the prescriber's clinical judgement decides where it sits. Prescriber discretion applies to every switch and dose decision, and the service needs a documented, unambiguous referral path for anyone who falls outside routine management.
- Suspected familial hypercholesterolaemia (very high LDL, strong family history of early cardiac events)
- Patients already under a cardiology or specialist lipid clinic
- LDL that stays persistently very high despite treatment
- Statin intolerance across more than one agent
- Pregnancy, or patients planning a pregnancy
- Significant hepatic impairment or complex polypharmacy
The clinical pathway from onboarding to first prescription
The intake asks for a cardiovascular risk history, current medication and family history, then a risk score is calculated. Before a statin is started, the prescriber needs a recent lipid panel and usually a liver function test: this is baseline safety information, not an optional extra, and it's one reason blood testing sits inside the wider service rather than being sold as a standalone product.
Once the results and risk assessment are reviewed, the prescriber issues an EPS-compatible private prescription and sets a review interval, generally a follow-up blood test some months later to confirm response and check for any liver enzyme changes, consistent with NICE's lipid modification guidance.
A lipid panel before the first prescription isn't optional due diligence, it's the baseline information the prescriber needs to make a safe decision.
Handling statin intolerance without losing the patient
Muscle aches are the most common reason patients stop a statin, and a good telehealth pathway treats that report as a triage event, not a support ticket. The usual next steps are a lower dose, an alternate-day schedule, or switching to a different statin before reaching for a non-statin option such as ezetimibe.
Newer options like PCSK9 inhibitors are typically specialist-initiated and fall outside what a private telehealth service should be prescribing directly, so they belong on the referral list rather than the formulary. Build muscle-symptom questions and clear safety-netting advice into the intake and any follow-up messaging from day one.
The GPhC, MHRA and NICE framing operators need to know
Statins are prescription-only medicines, so an independent prescriber makes the clinical call, working from NICE's lipid modification guidance rather than a fixed protocol. The superintendent pharmacist carries accountability for the dispensing side, and the same GPhC responsibilities and MHRA distance-selling rules apply here as to any other private prescribing service.
Muscle toxicity, while uncommon, is a serious adverse reaction operators need a working process for, not an afterthought. That means a live Yellow Card reporting workflow, so anything reported through intake or support actually reaches the MHRA rather than sitting in a support inbox.
The commonest reason a statin telehealth patient churns isn't the medicine failing, it's a muscle ache that nobody triaged properly.
Building the operational stack: repeats, reviews and monitoring
Once a patient is stable, this becomes a high repeat-rate, low-touch category, which is good for unit economics, but only if the repeat prescription cycle and the monitoring recall are built into the platform rather than chased manually. An annual review reminder, a blood test recall, and a clear escalation path if a result comes back outside range are the pieces that actually hold a lipid vertical together.
Skip that infrastructure and the vertical looks fine at launch, then quietly degrades as the patient base ages past its first prescription and nobody is prompted to recall them for a review.
Where PExpo fits
Adding a cholesterol vertical to an existing brand is mostly an infrastructure question: a regulated dispensing and superintendent layer, EPS-ready prescribing, a way to ingest and act on blood results, and a review-cycle engine that doesn't rely on someone remembering to chase patients. That's the layer PExpo runs underneath clinic and white-label brands already operating cardio-metabolic verticals.
For a brand that already has hypertension or diabetes live, cholesterol is usually the fastest additional vertical to stand up, because the monitoring and repeat infrastructure is already built; it just needs the lipid-specific pathway and referral rules layered on top.
Cholesterol and statin prescribing rewards operators who treat it as a repeat, monitored pathway rather than a one-off transaction. Get the lipid panel gate, the referral boundaries and the review cadence right, and it sits comfortably alongside an existing hypertension or diabetes vertical. Get in touch via our brands page or check pricing to see how it fits your existing stack.
Frequently asked questions
Can a UK telehealth service prescribe statins without GP involvement?
Yes, an independent prescriber can issue a private statin prescription without GP involvement, though writing to the patient's GP with a summary is good practice for continuity of care. Prescriber discretion applies to whether and what to prescribe in any individual case.
Do patients need a blood test before starting a statin online?
Yes, a recent lipid panel and usually a liver function test are standard before a prescriber starts a statin, and again at follow-up to check response and tolerability. Blood testing for this purpose typically sits inside the wider telehealth service rather than being offered as a standalone product.
What should happen if a patient reports muscle pain after starting a statin?
The pathway should treat it as a clinical triage event: the prescriber reviews the symptom, considers a lower dose, an alternate-day schedule or a different statin, and gives clear safety-netting advice on when to seek urgent care. Persistent or severe symptoms should prompt stopping the statin and referral rather than continued self-management.
